Epilepsy, Autoimmune Evaluation [A Test in Focus]

epilepsy-brochure-buttonA new epilepsy autoimmune evaluation is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. Below is a short video overview from Sean Pittock, M.D., discussing what providers should know about autoimmune epilepsy, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

testinfocus-test-info Similar Evaluations Include:

  • Many disorders of the central nervous system previously considered neurodegenerative and untreatable are now recognized as having an autoimmune cause.
  • Detection of one or more neural autoantibodies in serum or spinal fluid is consistent with a diagnosis of autoimmune epilepsy
  • Autoimmune epilepsy is not rare and is potentially treatable
  • Diagnosis is aided by testing autoantibody profiles in serum and spinal fluid
  • Occult cancer accompaniment is not uncommon
testinfocus-testutilization How to Use These Tests
As you consider autoimmune epilepsy in the differential diagnosis, the following may be clues leading to an autoimmune cause and use of the autoantibody profiles.

  • Subacute onset of cognitive or other neuropsychiatric symptoms
  • Treatment-resistant localization-related epilepsy of unknown cause

Serological findings are diverse and cannot be predicted by neurological phenotype. Thus evaluating with profiles of autoantibodies is appropriate.

  • Patients may present with a phenotype limited to seizures, without classic risk factors for epilepsy
  • Patients are usually resistant to standard antiepileptic drugs, but often become seizure free with immune therapies
  • Order profile EPIES (serum) or EPIEC (CSF)
  • EPIES — Serum

Brent Westra

Brent Westra is a Marketing Segment Manager at Mayo Medical Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.